David A. Siegel Rubius Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $245,640 - $688,860	-534,000 Reduced 94.78%	29,400 $13,000
Q2 2022 Aug 15, 2022	BUY	$0.79 - $5.98 $243,794 - $1.85 Million	308,600 Added 121.11%	563,400 $479,000
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $174,250 - $426,400	41,000 Added 19.18%	254,800 $1.4 Million
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $682,440 - $1.25 Million	70,500 Added 49.2%	213,800 $2.07 Million
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $1.96 Million - $2.88 Million	111,100 Added 345.03%	143,300 $2.56 Million
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $449,652 - $574,286	20,200 Added 168.33%	32,200 $786,000
Q1 2021 May 17, 2021	SELL	$8.02 - $32.01 $104,260 - $416,130	-13,000 Reduced 52.0%	12,000 $318,000
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $5,076 - $10,476	-1,200 Reduced 4.58%	25,000 $190,000
Q3 2020 Nov 16, 2020	SELL	$4.65 - $6.25 $19,530 - $26,250	-4,200 Reduced 13.82%	26,200 $131,000
Q2 2020 Aug 14, 2020	BUY	$4.01 - $6.88 $10,025 - $17,200	2,500 Added 8.96%	30,400 $182,000
Q1 2020 May 15, 2020	BUY	$3.74 - $9.84 $104,346 - $274,536	27,900 New	27,900 $124,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.